Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
about
Redefining the viral reservoirs that prevent HIV-1 eradicationConcentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV InfectionIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisHumanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1Genetic characterization and antiretroviral resistance mutations among treatment-naive HIV-infected individuals in Jiaxing, China.Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionHIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studyIntracellular drug concentrations.HIV protease inhibitors and obesityVery high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patientsFavipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study.Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.Nevirapine inhibits the anti-HIV activity of CD8+ cellsAntiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.Effects of political conflict-induced treatment interruptions on HIV drug resistanceInteractions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue.Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.Tissue penetration of antifungal agents.Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous systemVirological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire.Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Inflammation and pharmacokinetics: potential implications for HIV-infection.Pharmacogenetic considerations in the treatment of HIV.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.
P2860
Q26827255-6E1C03A5-34F1-4D94-9EBF-2842533D6656Q28468505-D7CBB4AF-79C7-4E36-B780-A1872AF1C519Q28486262-D0EE0A50-62A1-41F3-81B5-24636F3C1954Q28728527-2096F7F5-ABB8-4520-8761-4D1775CB0A7CQ33566910-C473D7F2-3C83-472F-A71D-5932CC33EF38Q34178412-4D61BFF0-FDA0-4140-9E7D-CF2655752E5FQ34481359-43FB52A8-B8A7-4666-8848-31BCFDA07C77Q34534986-79726081-0F4A-40D0-A36E-0E94F2F814D9Q34567127-BE0E928D-6F07-4794-91DA-F043A26FD318Q34792983-2FA4AF09-E195-4619-951B-20430C251683Q35004837-9672E0D5-9426-4CBD-A9D6-8F5990FE7020Q35005018-026E21F0-7055-40AD-AEA5-3C0570697845Q35065817-69E2450D-5CF4-4E72-8327-E0D6C8B0EA70Q36288297-5BC98C49-E154-449F-9178-A48D0170A828Q36288425-2311E184-05DC-499D-A0BC-2388DAA9EA15Q36290604-B61BE5B6-41D1-4A60-9AFB-8C97B5F56C8FQ36498717-C2014392-D49C-47CF-81F7-8F52CE00CD54Q36675900-236C309B-3320-462B-A49B-5F3A52D543B5Q36843910-63BFCBBA-E5E8-4830-B962-86FE9B0C4873Q36977376-B9C5D2F9-DA92-4718-A8AA-3AAFEC38C6D9Q37113947-D0EAA36F-D7D3-456D-B7D9-19682D055EA1Q37126494-6A6343B8-25D0-4EA9-A170-5AA9391A15E8Q37175897-4BD6D0AD-5360-48E2-BF07-61E98E687F48Q37232200-5FF9D181-60CC-4A3E-B3FF-503035941BA9Q37258762-01824B7E-EF04-40F8-BA4E-57D29D846313Q37335626-709C3292-8C2B-42DC-9697-76DF4558E306Q37335637-DDAA68C1-E6B0-4C3F-8EBE-2686F8F6FFFDQ37538706-341B52BF-3B72-43BF-AADD-CC0CDF295086Q37544911-259B4D51-E93C-4860-A6B1-3BB5FE085623Q37592018-217239F9-A143-44F1-BB33-7A5E4C32BF73Q37613239-585D52F2-7110-4598-B8BE-423956D279E8Q37621893-0C33D5C7-5BA0-4591-B544-9A984CD2AABCQ37798546-381973D3-B8E3-49E9-95FC-0CBFBA233EDFQ37826300-6DCC3695-3930-449F-B184-94928307366EQ37836908-B8F16FB8-7D4E-46EA-B6FC-1949FED5C834Q37866289-9F4B02DA-F779-49AE-A64B-3C900109B79DQ38051400-F72071E6-93F4-40C0-A975-CC5CB229366DQ38740792-58BF028C-95CB-442B-9549-4924BFCAFCC1Q38782609-B27282C7-7742-47FF-9410-E00C55D4667AQ38954109-7E0C3641-CC2B-4DD7-9ECC-F06EDF140CE7
P2860
Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intracellular Pharmacokinetics ...... Correlation with Drug Action.
@en
Intracellular Pharmacokinetics ...... Correlation with Drug Action.
@nl
type
label
Intracellular Pharmacokinetics ...... Correlation with Drug Action.
@en
Intracellular Pharmacokinetics ...... Correlation with Drug Action.
@nl
prefLabel
Intracellular Pharmacokinetics ...... Correlation with Drug Action.
@en
Intracellular Pharmacokinetics ...... Correlation with Drug Action.
@nl
P2093
P2860
P921
P1476
Intracellular Pharmacokinetics ...... Correlation with Drug Action.
@en
P2093
Anne-Marie Taburet
Caroline Bazzoli
Clotilde Le Tiec
Elisabeth Rey
France Mentré
Vincent Jullien
P2860
P356
10.2165/11318110-000000000-00000
P577
2010-01-01T00:00:00Z